To study the effect and mechanism of esketamine on skeletal muscle ischemia-reperfusion injury caused by tourniquet during arthroscopic knee surgery

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050980

Enrollment

Unknown

Registered

2021-09-09

Start date

2021-09-20

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skeletal muscle ischemia-reperfusion injury

Interventions

Experimental group:After anesthesia was stabilized, 0.5 mg/kg esketamine was administered to the patient before the tourniquet was applied.

Control group:After stabilization of anesthesia, saline was administered before the tourniquet was applied.

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-59 years, ASA I-II grade; 2. Knee arthroscopic surgery patients with upper tourniquet; 3. BMI 18.5-26.9kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Patients who are allergic to opioids and esketamine; 2. Patients with metabolic, renal or liver disease; 3. Patients using intraoperative glucocorticoids, dezocine, inhalation anesthetics and other drugs that affect ischemia-reperfusion; 4. Patients with symptomatic peripheral vascular disease or tourniquet contraindications; 5. Patients who have recently used antioxidant drugs or have a history of chronic pain.

Design outcomes

Primary

Measure	Time frame
MDA;IMA;	—

Countries

China

Contacts

Public ContactLin Chengxin

The First Affiliated Hospital of Guangxi Medical University

lin.chx@163.com+86 139 0786 5980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026